On the heels of a strong Zolgensma sales beat, Novartis' effort to expand the gene therapy's reach has suffered a setback. And a safety red flag is to blame. The FDA slapped a partial hold on a phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results